Stay Informed on Corporate Sustainability

Author: Jed Nykolle Harme

To support our clients with changing pharmacopoeial requirements, SGS ISL is introducing Polarised Light Microscopy to complement our existing XRPD for the introduction of raw material Asbestos testing in December 2025.

Author: Jed Nykolle Harme

Pharmaceutical companies are facing mounting challenges in meeting regulatory demands, accelerating product development and overcoming workforce shortages. To address these pressures, SGS is expanding its agile insourcing programme, embedding skilled scientific staff directly within client facilities.

Author: Jed Nykolle Harme

The Pharma Industry Awards 2025 has unveiled its shortlist, marking a pivotal moment in Ireland’s pharmaceutical calendar. Now in its 12th year, the programme stands as the country’s most prestigious celebration of excellence, innovation, and leadership across the life sciences.

Author: Jed Nykolle Harme

Pharma and life sciences remain at the forefront of global transformation, with resilience, innovation and agility emerging as the defining features of the sector’s growth. This edition highlights how excellence and adaptability are shaping both operations and outcomes, offering lessons well beyond healthcare. The Pharma Industry Awards has unveiled its shortlist, marking a pivotal moment in Ireland’s pharmaceutical calendar and underlining its role as a leading platform for recognising achievement. Operational strategy is equally significant, as SGS expands agile insourcing solutions, demonstrating how efficiency, scale and flexibility can safeguard competitiveness in a shifting market and meet growing global demand. Investor sentiment remains another crucial indicator. Atai Life Sciences hitting a 52-week high showcases confidence in innovation-led growth, underscoring the sector’s ability to capture capital, drive momentum and convert research investment into tangible results. These stories illustrate a sector not simply responding to challenges but actively reshaping them into opportunities. For leaders, the lesson is clear: excellence in standards, strategic agility, and innovation-driven sustainability are the cornerstones of long-term success and global impact.

Author: Chemanager

Merck has inaugurated its first climate-neutral life sciences production facility at Blarney, Cork, as part of a €440 million investment program in Ireland. The plant will produce critical filtration technologies to support vaccines, monoclonal antibodies, and advanced therapies while reducing cross-border dependencies.

Author: EURACTIV

Trump announces 100% tariffs on branded pharmaceuticals, sparking uncertainty for Ireland’s pharma sector. While the EU-US Joint Statement caps tariffs at 15%, Irish exporters and policymakers are assessing the potential impact on trade, investment, and supply chains amid ongoing legal and regulatory developments.

Author: Investing

Atai Life Sciences hits a 52-week high of $5.35, marking a 336% increase over the past year. Despite a Phase 2b trial setback, analyst optimism remains strong, reflecting growing investor confidence in Atai’s innovative mental health and psychedelic therapy pipeline.

Author: PRNnewswire

Rhode Island launches Ocean State Labs, its first life science incubator, to accelerate early-stage companies in therapeutics, tissue regeneration, and surgical innovation. Backed by a $45 million investment, the hub combines lab infrastructure, venture support, and academic partnerships to strengthen the state’s life sciences ecosystem.

Author: ILOVELIMERICK

The University of Limerick and Edwards Lifesciences have signed a Memorandum of Understanding to accelerate medical device innovation and talent development. The strategic partnership will support research, education, and process automation initiatives, strengthening Ireland’s biopharmaceutical and medtech ecosystem.

Author: Jed Nykolle Harme

The life sciences industry is entering a period defined not by incremental steps but by bold decisions that will shape the resilience of global healthcare.